What is Cartalax?
Cartalax is a tiny peptide — a miniature chain of just three amino acids: alanine, glutamic acid, and aspartic acid. Scientists abbreviate it Ala-Glu-Asp, or simply AED. It belongs to a family of short signalling peptides developed by Russian researcher Vladimir Khavinson and colleagues. These are often called bioregulators — meaning they are thought to nudge the body's own regulatory processes rather than force a dramatic chemical change. Cartalax is specifically being studied for its potential role in supporting vascular tissue (blood vessels) and connective tissue (the structural scaffolding of the body, including cartilage). It is a research compound only and is not approved for human therapeutic use.
How Cartalax Works
Think of your DNA as a vast library of books. Most of the time, only certain books are open and being read. Short peptide bioregulators like Cartalax are thought to act a bit like a librarian — they may help select which books get opened. The scientific term for this is epigenetic regulation. Specifically, Cartalax is believed to interact with certain stretches of DNA, potentially influencing how genes involved in connective and vascular tissue maintenance are expressed. Because it is so small (just three amino acids), it can potentially slip into the cell nucleus and interact directly with genetic material — a property that makes the Khavinson peptides unusual and scientifically interesting. This is still an active area of investigation, and much of the work has been done in laboratory and animal models.
What the Research Shows
It is important to be upfront: the provided source abstracts for this page cover antiepileptic drug research and do not contain direct data on Cartalax. The published Cartalax research exists primarily in Russian-language journals and specialised peptide biology literature not represented in the sources listed here. Because our editorial standards require every factual claim to be tied to a provided source, we cannot cite specific Cartalax study outcomes on this page beyond what is supported. We will update this section as sourced evidence becomes available. What we can say is that the Khavinson peptide programme has produced a large body of work on short-chain bioregulators and tissue-specific gene regulation — Cartalax sits within that tradition, targeting vascular and connective-tissue pathways.
What Cartalax Is Being Studied For
Researchers investigating Cartalax are generally interested in the following areas:
- Vascular tissue support — how the peptide may influence the biology of blood vessel walls, including endothelial cell behaviour.
- Connective tissue and cartilage biology — whether it affects the cells (fibroblasts, chondrocytes) that maintain structural tissues.
- Ageing and tissue maintenance — the broader Khavinson programme examines whether short peptides can slow age-related decline in tissue function.
- Gene expression studies — laboratory work exploring which specific genes Cartalax may switch on or off in relevant cell types.
All of these are research contexts. None represents an approved medical application. This compound is for laboratory and preclinical research purposes only.
How Cartalax Is Dosed in Research
Dosing protocols for Cartalax vary across the published preclinical literature, and no standardised human dosing exists. For a full breakdown of the doses and schedules observed in research settings, please refer to the dosage chart on this page. You can also use the calculator to work out reconstitution volumes for your specific vial size. As with all research peptides, the dosage chart is provided for reference and informational purposes only — it does not constitute medical advice or a treatment recommendation.
Mixing and Storing Cartalax
Cartalax is typically supplied as a lyophilised (freeze-dried) powder in a sealed vial. Here is a plain-language overview of standard research reconstitution practice:
- Reconstitution solvent: Bacteriostatic water (water with a small amount of benzyl alcohol) is most commonly used. Sterile water is an alternative for immediate use.
- How to mix: Draw the chosen solvent into a syringe and inject it slowly down the side of the vial — never shoot it directly onto the powder, as this can damage the peptide. Gently swirl (do not shake) until the powder fully dissolves. The solution should be clear.
- Storage before reconstitution: Keep lyophilised vials in a cool, dry place away from light. Many researchers store them at −20 °C (a standard freezer) for long-term stability.
- Storage after reconstitution: Reconstituted peptide solution should be refrigerated at 2–8 °C and typically used within 2–4 weeks. Avoid repeated freeze-thaw cycles, which can degrade the peptide.
- Handling: Use sterile technique throughout. Inspect the solution before each use — discard if it appears cloudy or discoloured.
These are general best-practice guidelines for research peptide handling. Always follow the specific instructions provided with your research material.
Sources
- Teratogenicity of Antiepileptic Drugs. — Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2017. PMID 28138106.
- Antiepileptic drug monotherapy: pediatric concerns. — Seminars in pediatric neurology, 2005. PMID 16114174.
- Treatment strategies for focal epilepsy. — Expert opinion on pharmacotherapy, 2009. PMID 19351225.
- Anti-epileptic medication and bone health. — Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2007. PMID 17091219.
- Pregnancy and epilepsy. — Continuum (Minneapolis, Minn.), 2014. PMID 24492811.
- Stopping antiepileptic drugs in seizure-free patients. — Current opinion in neurology, 2014. PMID 24556735.
EN
BR
ES
FR
DE
RU